Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) announced this morning that the company has signed a licensing agreement with Isodiol International Inc., one of the top producers and manufacturers of CBD consumer products, to distribute products to patients in Florida and Massachusetts.
Liberty Health Sciences will sell Isodiol’s branded products at its Liberty Cannabis Education Centers. Isodiol products are produced in a variety of different delivery systems and forms from Coffee, Topical’s, Capsules, Patches, and Oils. Their wide range of products will be provided to a number of different demographics.
Liberty Health Sciences invests and operates in U.S. cannabis markets where cannabinoids are medicinally and recreationally legal to consume and following strict guidelines when expanding into new markets. The company has a current market evaluation of 266.955M and is trading at $.90 per common share.
Marcos Agramont, CEO of Isodiol, gave this statement in the press release:
“Isodiol is excited to partner with a company that is equally committed to bring health and wellness to consumers around the globe. Florida and Massachusetts will further expand the marketplace for Isodiol and we look forward to establishing a long-term partnership with Liberty with further expansion down the road.”